Actinium Pharmaceuticals, Inc.
$1.44
▼
-0.97%
2026-04-21 05:27:01
www.actiniumpharma.com
ASE: ATNM
Explore Actinium Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$42.98 M
Current Price
$1.44
52W High / Low
$1.95 / $0.95
Stock P/E
—
Book Value
$0.25
Dividend Yield
—
ROCE
-82.74%
ROE
-1.67%
Face Value
—
EPS
$-1.09
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
25
Beta
-0.21
Debt / Equity
21.62
Current Ratio
6.2
Quick Ratio
6.2
Forward P/E
-1.92
Price / Sales
376.5
Enterprise Value
$-12.63 M
EV / EBITDA
0.35
EV / Revenue
-140.38
Rating
Buy
Target Price
$5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | OnKure Therapeutics, Inc. | $4.99 | — | $68.37 M | — | -112.02% | -74.39% | $5.06 / $1.7 | $4.11 |
| 2. | Lineage Cell Therapeutics, Inc. | $1.65 | — | $410.99 M | — | -21.52% | -1.05% | $2.09 / $0.4 | $0.18 |
| 3. | Shattuck Labs, Inc. | $7.88 | — | $538.88 M | — | -61.34% | -60.25% | $7.68 / $0.71 | $1.3 |
| 4. | Creative Medical Technology Holdings, Inc. | $2.26 | — | $9.13 M | — | -81.64% | -86.47% | $6.25 / $1.5 | $2.03 |
| 5. | Rallybio Corporation | $8.29 | — | $43.48 M | — | -56.97% | -15.01% | $11.49 / $1.9 | $10.97 |
| 6. | Alnylam Pharmaceuticals, Inc. | $310.49 | 133.51 | $41.46 B | — | 14.33% | 73.28% | $495.55 / $228.28 | $5.96 |
| 7. | Evaxion A/S | $4.49 | — | $37.11 M | — | -38.23% | -1% | $12.15 / $1.25 | $2.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0.09 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -6.41 M | -5.69 M | -7.5 M | -16.64 M | -7.5 M | — |
| Net Profit | -5.94 M | -5.13 M | -6.88 M | -15.94 M | -6.65 M | — |
| EPS in Rs | -0.19 | -0.16 | -0.22 | -0.51 | -0.21 | -0.37 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.09 M | 0 M | 0.08 M | 1.03 M |
| Operating Profit | -36.25 M | -42.12 M | -51.92 M | -34.1 M |
| Net Profit | -33.89 M | -38.24 M | -48.82 M | -33.02 M |
| EPS in Rs | -1.08 | -1.22 | -1.56 | -1.05 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 51.77 M | 76.9 M | 81.44 M | 114.19 M |
| Total Liabilities | 43.94 M | 44.14 M | 45.07 M | 47.71 M |
| Equity | 7.83 M | 32.76 M | 36.38 M | 66.48 M |
| Current Assets | 49.38 M | 74.51 M | 78.26 M | 110.94 M |
| Current Liabilities | 7.97 M | 8.15 M | 8.49 M | 10.63 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -24.58 M | -33.07 M | -47.34 M | 8.64 M |
| Investing CF | -0.1 M | -0.01 M | -0.15 M | -0.37 M |
| Financing CF | -0.22 M | 29.32 M | 14.87 M | 23.11 M |
| Free CF | -24.68 M | -33.08 M | -47.49 M | 8.28 M |
| Capex | -0.1 M | -0.01 M | -0.15 M | -0.37 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -92.14% | — | — |
| Earnings Growth % | 21.66% | -47.86% | — | — |
| Profit Margin % | — | -60269.14% | -3205.53% | — |
| Operating Margin % | — | -64098.77% | -3311.07% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -63123.46% | -3243.2% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.